A drug’s dosage and pharmacokinetic properties determine how quickly it acts, how intense its effects are, and how long it lasts. Higher doses increase drug concentration at receptor sites, producing a hyperbolic curve when pharmacologic response is plotted against drug dose. Converting this scale to a log-linear format results in a sigmoidal curve, better representing dose–response relationships.
For drugs following a one-compartment model, the pharmacologic response is directly proportional to the logarithm of the drug’s plasma concentration. The effect, E, of drug concentration, C, follows a mathematical equation that can be rearranged to solve for log C. However, after intravenous (IV) administration, drug concentration is calculated differently. Substituting pharmacokinetic parameters into the equation reveals a new expression with a slope of km/2.3.
The slope represents the linear decline of the drug's effect over time. Drugs with a higher m value require more frequent dosing to counteract rapidly decreasing responses. This is crucial for maintaining therapeutic efficacy, particularly for drugs with short half-lives.
For example, in controlled clinical pharmacology studies, intravenous administration of lysergic acid diethylamide (LSD) has been used to examine time-dependent drug effects. In these studies, the log concentration of LSD and the performance score—a quantitative measure of pharmacologic effect—decline linearly over time. This pattern is characteristic of many centrally acting drugs, in which effect duration depends on elimination half-life, as well as receptor desensitization and redistribution.
Understanding these relationships is essential for optimizing dosing regimens. Clinicians must balance drug potency, duration of action, and frequency of administration to achieve therapeutic effects while minimizing adverse reactions.
A drug’s dosage and pharmacokinetic properties influence the onset, intensity, and duration of its pharmacologic actions.
Higher drug dosage increases its receptor site concentration, yielding a hyperbolic curve when plotting pharmacologic response versus drug dose.
Here, changing to a log-linear scale results in the sigmoidal curve. For one-compartment model drugs, the pharmacologic response is proportional to log drug plasma concentration.
The effect, E, of drug concentration, C, is expressed as follows, which is solved for providing log C.
However, the post-IV dosing drug concentration is calculated differently, and mathematical substitutions yield another equation indicating the slope km/2.3.
Notably, the slope reflects the linear decline of the pharmacologic response over time. A drug with a higher m value requires frequent dosing to overcome rapidly declining responses.
For example, after the IV administration of lysergic acid diethylamide in healthy human subjects, the log concentration and the performance score, a measure of pharmacologic effect, decline linearly with time.
繁體中文
